💨 Abstract

Indian vaccine manufacturer Bharat Biotech has invested $75 million in a cell and gene therapy (CGT) facility in Telangana, aiming to launch new therapies within the next three years. The company is focusing on cell and gene therapies for oncology and rare diseases, which are expected to grow from $21.28 billion in 2024 to $117.46 billion by 2034.

Courtesy: theprint.in

Summarized by Einstein Beta 🤖